Back to Report Store Home

Frontier Pharma: Ophthalmology Therapeutics - Gene Therapies and First-in-Class Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune Signaling Drugs

  • Published: Oct-2017
  • Report Code: GBIHC457MR
  • Report Format: pdf

Description

List of Tables

Table 1: Ophthalmology Therapeutics, Global, Main Symptoms of Glaucoma, AMD, DR and DES, 2017 12

Table 2: Ophthalmology Therapeutics, Global, Prevalence of Major Ophthalmologic Disorders, 2017 13

Table 3: Ophthalmology Therapeutics, Global, Treatment Options Available for Glaucoma, 2017 21

Table 4: Ophthalmology Therapeutics, Global, Data for XXX as a Molecular Target, 2017 46

Table 5: Ophthalmology Therapeutics, Global, Data for XXX as a Molecular Target, 2017 47

Table 6: Ophthalmology Therapeutics, Global, Data for XXX as a Molecular Target, 2017 47

Table 7: Ophthalmology Therapeutics, Global, Data for XXX as a Molecular Target, 2017 48

Table 8: Ophthalmology Therapeutics, Global, Data for XXX as a Molecular Target, 2017 50

Table 9: Ophthalmology Therapeutics, Global, Data for XXX as a Molecular Target, 2017 51

Table 10: Ophthalmology Therapeutics, Global, Data for XXX as a Molecular Target, 2017 52

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards